Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Despite Harvard Medical School research published in July 2024 showing diabetes patients prescribed semaglutide faced over four times higher NAION risk (and weight loss patients faced over seven times higher risk) Novo Nordisks current Ozempic and Wegovy labels still mention only generic vision changes without specifically identifying NAION or permanent blindness as known risks
Obesity and its comorbidities, current treatment options and future perspectives: challenging bariatric surgery
Some members submit receipts for possible reimbursement, but coverage is not built into the model
Per Biospace: Following the White House deals, Novo said it would offer a self-pay option for Wegovy and Ozempic for $199 per month
